Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13464719 | 0.90 | MAPT (0.37) | MEN1MAPTKMT2AAAK1CYP1A2 | |
| SCHEMBL13464901 | 0.88 | CYP1A2 (0.42) | MAPTAAK1CYP1A2CYP2A6ROCK2 | |
| SCHEMBL2708168 | 0.88 | MEN1 (0.39) | MEN1MAPTKMT2AAAK1ROCK2 | |
| SCHEMBL9980105 | 0.85 | CYP1A2 (0.37) | CYP1A2CYP2A6MAOB | |
| SCHEMBL2756778 | 0.84 | MAPT (0.38) | MEN1MAPTKMT2AAAK1ROCK2 | |
| SCHEMBL9980285 | 0.81 | NR3C1 (0.33) | AAK1CYP1A2CYP2A6MAOAMAOB | |
| SCHEMBL2756598 | 0.80 | CYP1A2 (0.42) | MAPTAAK1CYP1A2CYP2A6ROCK2 | |
| SCHEMBL2756611 | 0.80 | CYP1A2 (0.34) | CYP1A2CYP2A6MAOB | |
| SCHEMBL13070868 | 0.79 | CYP1A2 (0.38) | MEN1MAPTKMT2ACYP1A2CYP2A6 | |
| SCHEMBL2707240 | 0.78 | MEN1 (0.39) | MEN1MAPTKMT2AAAK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MEN1 4292/4885MAPT 2923/4885KMT2A 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.